Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24424824 | 0.89 | CA12 (0.44) | MEN1KMT2AHTR2A | |
| SCHEMBL21955607 | 0.89 | HTR2A (0.31) | MEN1KMT2AHTR2A | |
| SCHEMBL2737210 | 0.89 | CA12 (0.44) | MEN1KMT2AHTR2A | |
| SCHEMBL21127039 | 0.87 | — | — | |
| SCHEMBL24424697 | 0.87 | — | — | |
| SCHEMBL12791352 | 0.87 | MEN1 (0.48) | MEN1KMT2A | |
| SCHEMBL5715676 | 0.85 | MEN1 (0.32) | MEN1KMT2AHTR2A | |
| SCHEMBL22790537 | 0.84 | HTR2A (0.36) | HTR2A | |
| SCHEMBL24218580 | 0.84 | — | — | |
| SCHEMBL25765922 | 0.84 | AOC3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238076-A1 | PROCESS FOR PRODUCING VASCULAR PROSTHESES | LUDWIG BOLTZMANN GESELLSCHAFT – ÖSTERREICHISCHE VEREINIGUNG ZUR FÖRDERUNG VON WISSENSCHAFTLICHEN FORSCHUNGEN (AT) | 2024-07-18 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230272148-A1 | THERMOPLASTIC POLY(URETHANE-UREA) POLYADDUCTS | TECHNISCHE UNIVERSITAET WIEN (AT) | 2023-08-31 | — | — | US | disclosed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOG (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOG (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-7494991-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS PHARMA, LLC (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070238747-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070142392-A1 | Uses of rifamycins | ACTIVBIOTICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007070084-A1 | USES OF RIFAMYCINS | ACTIVBIOTICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-7220738-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | MEN1 2450/4885KMT2A 3476/4885HTR2A 4326/4885 |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | MEN1 868/4885KMT2A 3204/4885HTR2A 911/4885 |
| US-20070142392-A1 | Uses of rifamycins | TNF, TLR6, IL6 | MEN1 3624/4885KMT2A 3755/4885HTR2A 4832/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | MEN1 4782/4885KMT2A 2957/4885HTR2A 4663/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | MEN1 4868/4885KMT2A 1865/4885HTR2A 4601/4885 |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | MEN1 4331/4885KMT2A 2000/4885HTR2A 2305/4885 |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | MEN1 718/4885KMT2A 2906/4885HTR2A 1745/4885 |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | CD47, FCGR2A, CD40 | MEN1 2859/4885KMT2A 2284/4885HTR2A 3413/4885 |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | PHOSPHO1, CHMP4B, SGMS1 | MEN1 1363/4885KMT2A 2031/4885HTR2A 2189/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | MEN1 4801/4885KMT2A 2014/4885HTR2A 4796/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885HTR2A 3621/4885 |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | MEN1 1339/4885KMT2A 1375/4885HTR2A 4122/4885 |
| US-20070238747-A1 | Rifamycin analogs and uses thereof | RIF1, HDAC5, HDAC4 | MEN1 4056/4885KMT2A 1979/4885HTR2A 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.